Ocugen, Inc. (NASDAQ:OCGN) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts assign Ocugen an average rating of "Moderate Buy" (four buys, one sell) with a 12‑month consensus target of $9.75, and recent covers include Oppenheimer (outperform, $10) and Canaccord ($12).
• Q1 results showed an EPS miss (‑$0.06 vs. ‑$0.05 est.) but a revenue beat of $1.53M, and the stock dropped roughly 19.5% amid wider losses and elevated trading volume.
• The company priced a $115M convertible (6.75%, at 90% of par, convert at ≈$2.68) to refinance a high‑interest loan and extend runway into 2028, which reduces near‑term cash outflows but raises dilution and cost concerns despite positive 12‑month Phase 2 data for OCU410 supporting a path toward registrational trials.

Ocugen, Inc. (NASDAQ:OCGN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $9.75.

A number of equities research analysts recently issued reports on the company. Oppenheimer assumed coverage on Ocugen in a research report on Wednesday, March 11th. They issued an "outperform" rating and a $10.00 target price on the stock. Wall Street Zen lowered Ocugen from a "hold" rating to a "sell" rating in a research report on Saturday, April 4th. Weiss Ratings reissued a "sell (e+)" rating on shares of Ocugen in a research report on Thursday, January 22nd. HC Wainwright lifted their target price on Ocugen from $7.00 to $10.00 and gave the company a "buy" rating in a research report on Wednesday, March 25th. Finally, Canaccord Genuity Group assumed coverage on Ocugen in a research report on Tuesday, March 17th. They issued a "buy" rating and a $12.00 target price on the stock.

Ocugen Stock Down 19.5%

Shares of Ocugen stock opened at $1.49 on Wednesday. The business's 50 day simple moving average is $1.88 and its 200 day simple moving average is $1.59. Ocugen has a 52-week low of $0.64 and a 52-week high of $2.73. The firm has a market cap of $504.39 million, a PE ratio of -6.48 and a beta of 2.30. The company has a debt-to-equity ratio of 8.04, a quick ratio of 1.06 and a current ratio of 1.06.

Ocugen (NASDAQ:OCGN - Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.01). Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%. The firm had revenue of $1.53 million during the quarter, compared to analyst estimates of $0.42 million. On average, analysts predict that Ocugen will post -0.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in shares of Ocugen by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 15,223,585 shares of the company's stock worth $24,814,000 after purchasing an additional 450,904 shares during the last quarter. Millennium Management LLC increased its position in shares of Ocugen by 29.7% during the 4th quarter. Millennium Management LLC now owns 5,396,417 shares of the company's stock worth $7,285,000 after purchasing an additional 1,234,268 shares during the last quarter. UBS Group AG increased its position in shares of Ocugen by 373.2% during the 4th quarter. UBS Group AG now owns 4,849,353 shares of the company's stock worth $6,547,000 after purchasing an additional 3,824,474 shares during the last quarter. State Street Corp increased its position in shares of Ocugen by 193.6% during the 4th quarter. State Street Corp now owns 3,978,738 shares of the company's stock worth $5,371,000 after purchasing an additional 2,623,361 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Ocugen by 3.9% during the 4th quarter. Geode Capital Management LLC now owns 3,819,242 shares of the company's stock worth $5,159,000 after purchasing an additional 142,050 shares during the last quarter. Institutional investors and hedge funds own 10.27% of the company's stock.

Ocugen News Roundup

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Clinical progress: Management reported positive 12‑month Phase 2 data for OCU410 in geographic atrophy (roughly ~30% lesion growth reduction versus control) and said OCU400 and OCU410ST enrollment for registration trials is complete — supports a clear path to registrational Phase 3 trials and potential BLAs by 2027. Read More.
• Positive Sentiment: Balance‑sheet step: Company priced a private $115M convertible senior notes offering and plans to use ~ $32.7M of net proceeds to fully repay a high‑interest Avenue loan, which should reduce near‑term cash outflows and extend runway into 2028 (per guidance). Read More.
• Neutral Sentiment: Revenue beat but small base: Q1 revenue of $1.53M topped estimates (~$0.42M) — positive signal of commercial/other revenue pickup but absolute dollars remain small relative to development spending. Read More.
• Neutral Sentiment: High trading volume and institutional activity noted in market commentaries — increases volatility and potential for bigger intraday moves. Read More.
• Negative Sentiment: Earnings miss & widening loss: Q1 EPS was ($0.06), missing consensus (~($0.05)) and reflecting a widening loss year‑over‑year; company posted very negative net margin and ROE metrics, which pressured sentiment. Read More.
• Negative Sentiment: Dilution and financing terms: The notes bear 6.75% interest, were priced at 90% of par, and convert at ~$2.68/share (≈45% premium to last close) — conversion potential and the offering discount raise near‑term dilution and cost concerns for equity holders. Read More.
• Negative Sentiment: Market reaction: Coverage and headlines focused on wider losses and the debt offering, driving selling pressure despite the pipeline update — contributing to the stock moving lower. Read More.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.